The Wistar Institute of Anatomy and Biology was founded in 1892 at its current site to operate as an independent research entity dedicated to the maintenance and enhancement of its anatomical collection and to """"""""the conduct of any other work for the increase of scientific knowledge."""""""" Over its history, The Wistar Institute has emerged as one of the nation's leading private basic research institutions. In recognition of its contributions in cancer research, the Institute received a Cancer Center Support (CCSG) and was designated by the National Cancer Institute (NCI) as a federally approved Cancer Center in 1972, specializing in basic research. In 1976 the NCI funded the addition of a Cancer Wing to the original Main Building. In 2002 Dr. Russel Kaufman was appointed Director and CEO of The Wistar Institute Cancer Center (Cancer Center). Following his arrival, Dr. Kaufman has led a restructuring of the Research Programs and an extensive review of the Shared Resources. Research at the Institute is organized into three programs: Gene Expression and Regulation; Cellular and Molecular Oncogenesis; and Immunology. Investigators are recognized for their leading contribution in gene regulation and chramatin modification, melanoma research, vaccine development, and translational research. The goals of the current CCSG application are to further expand on our success in these areas by recruiting new faculty to the Institute and by the Institute and by Providing an environment and resource to promote the success of the members of the Cancer Center. The Cancer Center will emphasize the study of macromolecular transcriptional complexs, mouse models of human cancer, organotypic model systems, antigen recognition and processing, immune cell trafficking, stem cell development, and systems biology. These areas of investigation will complement and expand existing areas of excellence and provide novel insights into the biology of cancer, as well as targets for cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-38
Application #
7019149
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1978-09-01
Project End
2008-02-29
Budget Start
2006-03-29
Budget End
2007-02-28
Support Year
38
Fiscal Year
2006
Total Cost
$2,595,926
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Fukumoto, Takeshi; Magno, Elizabeth; Zhang, Rugang (2018) SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Mol Cancer Res 16:1819-1825
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Colón, Krystal; Speicher, David W; Smith, Peter et al. (2018) S100a14 is Increased in Activated Nk Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-Nk crosstalk. J Acquir Immune Defic Syndr :
Schug, Zachary T (2018) Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon ""Bi""-cycle. Biochemistry 57:889-890
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705

Showing the most recent 10 out of 741 publications